Article thumbnail

Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species

By Lisa E. Hensley, Sabue Mulangu, Clement Asiedu, Joshua Johnson, Anna N. Honko, Daphne Stanley, Giulia Fabozzi, Stuart T. Nichol, Thomas G. Ksiazek, Pierre E. Rollin, Victoria Wahl-Jensen, Michael Bailey, Peter B. Jahrling, Mario Roederer, Richard A. Koup and Nancy J. Sullivan

Abstract

A major challenge in developing vaccines for emerging pathogens is their continued evolution and ability to escape human immunity. Therefore, an important goal of vaccine research is to advance vaccine candidates with sufficient breadth to respond to new outbreaks of previously undetected viruses. Ebolavirus (EBOV) vaccines have demonstrated protection against EBOV infection in nonhuman primates (NHP) and show promise in human clinical trials but immune protection occurs only with vaccines whose antigens are matched to the infectious challenge species. A 2007 hemorrhagic fever outbreak in Uganda demonstrated the existence of a new EBOV species, Bundibugyo (BEBOV), that differed from viruses covered by current vaccine candidates by up to 43% in genome sequence. To address the question of whether cross-protective immunity can be generated against this novel species, cynomolgus macaques were immunized with DNA/rAd5 vaccines expressing ZEBOV and SEBOV glycoprotein (GP) prior to lethal challenge with BEBOV. Vaccinated subjects developed robust, antigen-specific humoral and cellular immune responses against the GP from ZEBOV as well as cellular immunity against BEBOV GP, and immunized macaques were uniformly protected against lethal challenge with BEBOV. This report provides the first demonstration of vaccine-induced protective immunity against challenge with a heterologous EBOV species, and shows that Ebola vaccines capable of eliciting potent cellular immunity may provide the best strategy for eliciting cross-protection against newly emerging heterologous EBOV species

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2873919
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys.
  2. (2006). A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.
  3. (2003). Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.
  4. (2006). Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry.
  5. (2009). Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.
  6. (2006). Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor.
  7. (2000). Development of a preventive vaccine for Ebola virus infection in primates.
  8. (2007). Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.
  9. eds (2005) Virus Taxonomy:
  10. (1999). Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro.
  11. (1983). Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management.
  12. (2009). Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors.
  13. (2007). High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings.
  14. (2006). Immune protection of nonhuman primates against Ebola virus with single lowdose adenovirus vectors encoding modified GPs.
  15. (2005). Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.
  16. (2002). MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform.
  17. (2008). Magnitude and quality of vaccine-elicited T-cell responses in the control of immunodeficiency virus replication in rhesus monkeys.
  18. (2001). Monitoring HIV-specific CD8+ T cell responses by intracellular cytokine production.
  19. (2007). Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys.
  20. (2008). Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda.
  21. (2003). Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection.
  22. (1989). PHYLIP - Phylogeny Inference Package (Version 3.2).
  23. (1997). Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination.
  24. (2006). Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys.
  25. (2005). Replicationdefective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates.
  26. (1994). Sanchez A
  27. (2007). Status and challenges of filovirus vaccines.
  28. (2008). Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.
  29. (2007). Successful topical respiratory tract immunization of primates against Ebola virus.
  30. (2007). The ecology of Ebola virus.
  31. (1987). The neighbor-joining method: a new method for reconstructing phylogenetic trees.
  32. (1992). The rapid generation of mutation data matrices from protein sequences.
  33. (2003). Towards a vaccine against Ebola virus.
  34. (2005). Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys.